|
Endoscopic Therapy Or Surgery for Early Colon Cancer
RECRUITINGPhase 3Sponsored by Norwegian Department of Health and Social Affairs
Actively Recruiting
PhasePhase 3
SponsorNorwegian Department of Health and Social Affairs
Started2025-08-25
Est. completion2033-09-01
Eligibility
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT06940947
Summary
The trial is a randomized head-to-head comparison of the benefits, harms and burdens of endoscopic full-thickness resection (eFTR), a novel, minimally invasive endoscopic treatment modality, for early colon cancer as compared to standard-of-care surgery.
Eligibility
Healthy volunteers accepted
Inclusion Criteria: * Newly diagnosed biopsy-confirmed colon cancer (adenocarcinoma) with macroscopic suspicion of submucosal invasion considered removable by EFTR as deemed by the local multidisciplinary team (MDT) at the participating center * Size ≤20 mm in diameter as deemed by the colonoscopist * No presence of histopathological high-risk features in biopsy (high grade tumor growth, budding grade 2 or 3, or lymphovascular invasion) * Patient eligible for surgical removal as deemed by the local MDT at the participating center * Endoscopic images or video of the tumor * No sign of disease beyond T2N0M0 on pre-treatment imaging, biopsy sampling, and radiographic and clinical evaluation * No contraindication for any of the two treatment arms * Written informed consent * No prior or synchronous CRC * No other malignancy which is not cured * No more than 10 adenomas or serrated polyps * No genetic cancer syndrome (adenomatous or serrated polyposis syndrome; Lynch or Lynch-like syndrome) * No inflammatory bowel disease
Conditions2
CancerColon Cancer
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhasePhase 3
SponsorNorwegian Department of Health and Social Affairs
Started2025-08-25
Est. completion2033-09-01
Eligibility
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT06940947